🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07536607
Starting soon Observational

Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients

NCT07536607 · tracked via the Priya Life Science China tracker
Sponsor
Chinese PLA General Hospital
Phase
Observational
Started
2026-04-20
Last updated
2026-04-17

Condition(s) studied

Coronary Artery Disease

Investigational drug(s) / intervention(s)

there is no intervention in this study

there is no intervention in this study: there is no intervention

Study summary

For patients with severe calcification or complex non-calcified plaques, we investigate wether PCCT can enable non-invasive, in vivo precise differentiation and quantitative measurement of plaque components (e.g., spotty calcification, necrotic core, fibrous tissue). Further we also study wether these quantitative imaging features can independently predict the risk of MACE in the short term and long term

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criter: * Adult patients (≥18 years) with clinically diagnosed coronary artery disease or undergoing CCTA for chest pain/heart failure symptoms. * Able and willing to provide informed consent and complete scheduled follow-up visits. Exclusion Criteria: * History of iodine contrast agent allergy. * Severe renal insufficiency (eGFR \< 30 mL/min/1.73 m²). * History of prior coronary artery bypass grafting (CABG). * Pregnant or lactating women

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Chinese PLA General Hospital Beijing China

More Chinese PLA General Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07536607 on ClinicalTrials.gov ↗ ← All trials in China